Robert F. Kennedy, Jr. (Aaron Schwartz/Sipa USA/Sipa via AP Images)
January 22, 2025 11:50 AM ESTUpdated 01:56 PM
FDA+
Law

RFK Jr. says he’ll di­vest in­ter­ests in CRISPR Ther­a­peu­tics if con­firmed for HHS chief

Zachary Brennan

Senior Editor

HHS Sec­re­tary nom­i­nee Robert F. Kennedy Jr. will di­vest his in­ter­ests in sev­er­al bio­phar­ma com­pa­nies, in­clud­ing CRISPR Ther­a­peu­tics and Drag­on­fly Ther­a­peu­tics, if con­firmed by the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Bio­gen makes cuts across its re­search unit, shift­ing fo­cus to ‘ex­ter­nal op­por­tu­ni­ties’

'No mir­a­cles': What Re­gen­eron's George Yan­copou­los re­al­ly thinks of AI

Chi­nese start­up be­gins first tri­al of in vi­vo CRISPR ther­a­py for blood dis­ease

GLP-1s can cut the risk of Alzheimer’s. What does that mean for No­vo Nordisk?

US with­draw­al from WHO could jeop­ar­dize in­for­ma­tion shar­ing

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times